Source: Eur Respir J 2013; 41: 262-269
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Vancheri Carlo, du Bois Roland M.. A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer. Eur Respir J 2013; 41: 262-269

Member's Comments

No comment yet.

Related content which might interest you: Challenges in idiopathic pulmonary fibrosis trials: the point on end-points Source: Eur Respir Rev 2011; 20: 195-200 Year: 2011 Contemporary surgical issues in NSCLC treatment Source: Annual Congress 2007 - PG7 - Thoracic oncology: nonsmall cell lung cancer Year: 2007 Can clinical data predict rapid decline of lung function in idiopathic pulmonary fibrosis (IPF) patients? Source: International Congress 2017 – IPF: from the bench to the bedside Year: 2017 Emerging potential treatments: new hope for idiopathic pulmonary fibrosis patients? Source: Eur Respir Rev 2011; 20: 201-207 Year: 2011 The effect of pirfenidone on impaired lung function in patients with idiopathic pulmonary fibrosis (IPF) from Czech IPF registry Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema Source: Eur Respir J 2011; 37: 176-183 Year: 2011 Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes Source: Eur Respir Rev 2012; 21: 161-167 Year: 2012 Assessment of exercise capacity after lobectomy in patients with COPD Source: Annual Congress 2007 - Lung function parameters before and after thoracic surgery Year: 2007 The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 25: 96-103 Year: 2005 Effect of baseline FVC on lung function decline with nintedanib in patients with IPF Source: International Congress 2015 – Treatment of IPF Year: 2015 Clinical characteristics, haemodynamics, and survival in patients with combined pulmonary fibrosis and emphysema and associated pulmonary hypertension Source: Annual Congress 2008 - Pulmonary vascular medicine Year: 2008 T-cell pathways in lung tissue of patients with advanced COPD and IPF requiring lung transplantation Source: International Congress 2016 – Mechanisms of disease Year: 2016 Clinical profile of idiopathic pulmonary fibrosis with lung cancer Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis? Year: 2011 Is the COPD-index a significant prognostic factor of functional results of lobectomy in COPD patients? Source: Annual Congress 2007 - Lung function parameters before and after thoracic surgery Year: 2007 Estimated postoperative pulmonary function and 6 months recovery for lobectomized lung cancer patients with and without COPD Source: International Congress 2016 – Surgical strategy for complex diseases Year: 2016 Idiopathic pulmonary fibrosis: Gender differences in survival and functional decline. A retrospective study Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Impairment of pulmonary function after bronchogenic carcinoma resection in COPD patients Source: Annual Congress 2005 - New insights into prognosis in thoracic surgical oncology Year: 2005 Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment Source: International Congress 2016 – IPF treatment I Year: 2016 Generalisability of recent clinical trials in idiopathic pulmonary fibrosis to everyday clinical practice Source: International Congress 2015 – Treatment of IPF Year: 2015